Hormonal
Phentermine-topiramate produces greater weight loss than GLP-1 receptor agonists, but GLP-1 agonists carry a higher risk of adverse events.
If you are looking for the maximum possible weight loss number, phentermine-topiramate may outperform GLP-1 drugs like semaglutide. However, this comes with a higher risk of side effects. GLP-1s offer a better safety profile regarding adverse events and provide proven cardiovascular protection, making them a preferred choice for patients with heart disease risks despite slightly lower weight loss efficacy.
It found that, in order of efficacy, phentermine-topiramate showed the greatest weight loss (odds ratio [OR]: 8.02), followed by GLP-1 receptor agonists (OR: 6.33), and naltrexone-bupropion (OR: 2.69). Additionally, there was a higher risk of adverse events with GLP-1 agonists and orlistat
Why this rating
Based on a cited meta-analysis of randomized controlled trials, though the paper itself is a review.
Source
Obesidad, el papel del gastroenterólogo
Valeria Atenea Costa et al. · Revista Colombiana de Gastroenterología · 2024
DOI 10.22516/25007440.1192
More from this paper
- Semaglutide 2.4 mg weekly reduces cardiovascular mortality, myocardial infarction, and stroke in overweight/obese patients without diabetes but with cardiovascular disease.Strong
- Intragastric balloons (IGB) are effective for weight loss but carry risks of dehydration, readmission, and reintervention, with saline-filled balloons outperforming air-filled ones.Good
- Endoscopic Sleeve Gastroplasty (ESG) achieves 16-20% total weight loss at 12 months and improves metabolic markers without worsening GERD.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →